NEW DELHI: India calls itself the pharmacy of the world. It supplies 20 per cent of the world’s medicines, exports to over 200 countries and hosts more US FDA-approved manufacturing plants than any country outside the United States. Yet for all that industrial muscle, the business of actually selling, marketing and distributing those medicines remains, in much of the industry, a affair of spreadsheets, disconnected software, manual workflows and delayed reporting. SwishX, a Bengaluru-based startup launched on Tuesday, thinks agentic artificial intelligence can fix that — and is betting $2.2m in seed funding that it is right.
The company has raised that sum from Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures and other investors, and is pitching itself as the world’s first agentic AI platform built exclusively for pharmaceutical and medtech companies. The targets are ambitious: $5m in contracted annual recurring revenue and more than 100 enterprise clients by the end of the current financial year.
The problem it is solving
The pain points are real and well-documented. Pharma companies operating in emerging markets routinely struggle to identify which of thousands of government tenders they have a genuine shot at winning, where revenue is leaking, what is actually moving off retailer shelves, and whether their marketing efforts to engage doctors are producing any results. India alone has over 1.2 million pharmacies — compared with roughly 100,000 in the United States — and between 30 and 60 per cent of procurement flows through government tenders, making commercial complexity an order of magnitude greater than in developed markets.
SwishX’s answer is a suite of AI agents that capture siloed data, automate business workflows and build what the company calls a functional memory to accelerate execution. The platform spans four products: Tender IQ, which automates tender and RFP evaluation; Contract IQ, which handles hospital rate contract automation; Marketing IQ, which manages engagement between medical representatives and healthcare professionals; and Channel IQ, which oversees channel engagement. The company says the platform can improve revenue outcomes by up to 30 per cent.
The practical applications are striking. The platform can autonomously evaluate thousands of tenders globally, surface high-probability win opportunities, analyse documents running to 500-plus pages, recommend likely winning pricing and draft proposals within minutes. It can also convert lengthy marketing PDFs into personalised video reels for doctors in a single day — a process that previously took weeks.
A market worth getting right
The commercial opportunity is not small. India, Australia and Singapore combined represent a $400bn pharma and medtech market, with commercial operations projected to reach $770bn by 2033 at a compound annual growth rate exceeding 12 per cent. Industry estimates suggest AI could unlock between $60bn and $110bn in annual value globally in the sector. SwishX is starting with India and plans to expand into Latin America, Southeast Asia, the Middle East, Africa and Eastern Europe.
Dushyant Sapre, founder and chief executive, SwishX, says: “India’s pharma sector drives revenues of over $65bn, and emerging markets combined drive $400bn while distributing into over 200 countries. Manufacturing and R&D have become genuinely world-class, but how these companies sell, market and distribute is still stuck in the past. Companies often struggle to know where losses are happening, what is selling, which tenders matter most, or how effectively teams are executing in the market. AI agents change that completely. The next big transformation in this industry is not going to happen in the lab. It is going to happen in how these companies go to market. For the first time, companies can move to real-time autonomous execution.”
Built for emerging-market complexity
SwishX is explicit that it is not a CRM or a reporting tool. It is, in the company’s framing, a system of action — one that not only turns complex data into decisions but helps teams execute those decisions at scale. The platform is SOC-2 compliant with data encryption in transit and at rest, a non-trivial credential in a sector where data sensitivity is acute.
The long-term vision is broader still: a vertically integrated AI system spanning the entire life sciences value chain, from faster generic and biosimilar drug discovery to autonomous multi-market commercial execution. For now, SwishX is anchored where the pain is most immediate and the returns most measurable — in the unglamorous but commercially critical work of getting medicines sold, tendered and distributed efficiently.
The lab has had its revolution. The sales floor is next.
